JP2022536408A - アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法 - Google Patents

アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法 Download PDF

Info

Publication number
JP2022536408A
JP2022536408A JP2022515975A JP2022515975A JP2022536408A JP 2022536408 A JP2022536408 A JP 2022536408A JP 2022515975 A JP2022515975 A JP 2022515975A JP 2022515975 A JP2022515975 A JP 2022515975A JP 2022536408 A JP2022536408 A JP 2022536408A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
aldh2
alcohol
acetaldehyde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022515975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536408A5 (enExample
Inventor
ケイ．ワイ． ジャン、エドワード
Original Assignee
イーケイワイジェイ コンサルティング ツー、エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーケイワイジェイ コンサルティング ツー、エルエルシー filed Critical イーケイワイジェイ コンサルティング ツー、エルエルシー
Publication of JP2022536408A publication Critical patent/JP2022536408A/ja
Publication of JP2022536408A5 publication Critical patent/JP2022536408A5/ja
Priority to JP2025034659A priority Critical patent/JP2025093991A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022515975A 2019-05-23 2020-05-22 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法 Pending JP2022536408A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025034659A JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852000P 2019-05-23 2019-05-23
US62/852,000 2019-05-23
PCT/US2020/034273 WO2020237172A1 (en) 2019-05-23 2020-05-22 Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025034659A Division JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2022536408A true JP2022536408A (ja) 2022-08-15
JP2022536408A5 JP2022536408A5 (enExample) 2023-05-08

Family

ID=73458156

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515975A Pending JP2022536408A (ja) 2019-05-23 2020-05-22 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法
JP2025034659A Pending JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025034659A Pending JP2025093991A (ja) 2019-05-23 2025-03-05 アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法

Country Status (7)

Country Link
US (1) US20220226286A1 (enExample)
EP (1) EP3973030A4 (enExample)
JP (2) JP2022536408A (enExample)
KR (1) KR20220012903A (enExample)
CN (2) CN114144493A (enExample)
TW (1) TW202110437A (enExample)
WO (1) WO2020237172A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102879756B1 (ko) 2022-11-11 2025-11-12 대한민국 이상지질혈증 예측 또는 진단용 snp 마커 및 이의 용도
KR102893400B1 (ko) 2022-11-21 2025-12-02 대한민국 당뇨병 예측 또는 진단용 hectd4 snp 마커 및 이의 용도

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6468319A (en) * 1987-09-09 1989-03-14 Nonogawa Shoji Yk Anti-inflammatory
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
JP2002542282A (ja) * 1999-04-22 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ 栄養補助食品または薬物として有用な、カルニチンおよびリン酸イノシトール含有組成物
JP2003519173A (ja) * 1999-12-30 2003-06-17 アンシル ファーマシューティカルズ，インコーポレイテッド 薬学的製剤用臭気マスキングコーティング
WO2007017139A1 (en) * 2005-07-29 2007-02-15 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP2011051942A (ja) * 2009-09-03 2011-03-17 Glovia:Kk 認知症治療薬
WO2011043365A1 (ja) * 2009-10-07 2011-04-14 学校法人武庫川学院 遺伝子型判定方法
JP2013512930A (ja) * 2009-12-07 2013-04-18 ラプター セラピューティックス インコーポレイテッド ４−メチルピラゾール製剤
JP2013536238A (ja) * 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法
WO2016042205A1 (en) * 2014-09-15 2016-03-24 Biohit Oyj Preparations for treatment and prevention of alcohol flushing and alcohol-induced hypersensitivity reactions
WO2018091609A1 (en) * 2016-11-17 2018-05-24 Amalicon Holding Ag Formulation comprising 4-methylpyrazole

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW271400B (enExample) * 1992-07-30 1996-03-01 Pfizer
WO2008112164A2 (en) * 2007-03-08 2008-09-18 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6468319A (en) * 1987-09-09 1989-03-14 Nonogawa Shoji Yk Anti-inflammatory
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
JP2002542282A (ja) * 1999-04-22 2002-12-10 シグマ−タウ・ヘルスサイエンス・ソシエタ・ペル・アチオニ 栄養補助食品または薬物として有用な、カルニチンおよびリン酸イノシトール含有組成物
JP2003519173A (ja) * 1999-12-30 2003-06-17 アンシル ファーマシューティカルズ，インコーポレイテッド 薬学的製剤用臭気マスキングコーティング
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
JP2009516639A (ja) * 2005-07-29 2009-04-23 ティーマ ファウンデーション アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物
WO2007017139A1 (en) * 2005-07-29 2007-02-15 Tima Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
JP2011051942A (ja) * 2009-09-03 2011-03-17 Glovia:Kk 認知症治療薬
WO2011043365A1 (ja) * 2009-10-07 2011-04-14 学校法人武庫川学院 遺伝子型判定方法
JP2013512930A (ja) * 2009-12-07 2013-04-18 ラプター セラピューティックス インコーポレイテッド ４−メチルピラゾール製剤
JP2013536238A (ja) * 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法
WO2016042205A1 (en) * 2014-09-15 2016-03-24 Biohit Oyj Preparations for treatment and prevention of alcohol flushing and alcohol-induced hypersensitivity reactions
JP2017527595A (ja) * 2014-09-15 2017-09-21 ビオヒット・ユルキネン・オサケユキテュアＢｉｏｈｉｔ Ｏｙｊ アルコールフラッシング反応およびアルコール誘発性過敏反応の治療および予防用製剤
WO2018091609A1 (en) * 2016-11-17 2018-05-24 Amalicon Holding Ag Formulation comprising 4-methylpyrazole

Also Published As

Publication number Publication date
EP3973030A1 (en) 2022-03-30
JP2025093991A (ja) 2025-06-24
KR20220012903A (ko) 2022-02-04
WO2020237172A1 (en) 2020-11-26
EP3973030A4 (en) 2023-05-31
TW202110437A (zh) 2021-03-16
US20220226286A1 (en) 2022-07-21
CN119909065A (zh) 2025-05-02
CN114144493A (zh) 2022-03-04

Similar Documents

Publication Publication Date Title
US20200085807A1 (en) Administration of ethyl 3-[(2-{[4-(hexyloxycarbonyl-aminoiminomethyl)phenyl-amino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate
US9925174B2 (en) Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
AU2004258984B2 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
JP7069253B2 (ja) 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン
JP2025093991A (ja) アルコール誘発性皮膚紅潮の治療および緩和のための組成物および方法
CN109890366B (zh) 治疗心血管疾病的组合药物及其制备和使用方法
TW201919622A (zh) 高劑量戊苯那嗪（valbenazine）調配物及組合物、方法以及相關套組
US20220288048A1 (en) Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
JP2022521233A (ja) 桂皮酸を含む組成物及びその使用方法
JP2009500420A (ja) エスゾピクロン及びｏ−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
TWI777059B (zh) 肌肉減少症之預防劑及治療劑
JP5101306B2 (ja) 糖尿病治療剤
US20050182097A1 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
JP2013526503A (ja) キサンチンオキシダーゼ阻害剤とアンジオテンシンｉｉ受容体アンタゴニストとの合剤およびその使用
TW200920348A (en) Combination of picotamide with nafronyl
CN110623955A (zh) Wnk激酶抑制剂在预防和/或治疗高原病中的用途
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
JP6707471B2 (ja) ピロールカルボキサミドの固形組成物
JP2024540241A (ja) 治療上の使用のためのアンブロキソールの修飾形態
KR20250123927A (ko) 간질성 폐 질환을 치료하기 위한 lpa1 길항제
TW202440089A (zh) 用於治療間質性肺病之lpa1拮抗劑
US20140030329A1 (en) Methods for Treating Insomnia
HK40007061A (en) Pharmaceutical compositions of treating cardiovascular diseases, preparation thereof, and method of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230424

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241105